Precigen Revenue and Competitors

Location

$525.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Precigen's estimated annual revenue is currently $99M per year.(i)
  • Precigen's estimated revenue per employee is $942,667
  • Precigen's total funding is $525.8M.
  • Precigen's current valuation is $667.8M. (January 2022)

Employee Data

  • Precigen has 105 Employees.(i)
  • Precigen grew their employee count by -1% last year.

Precigen's People

NameTitleEmail/Phone
1
Pres & CEOReveal Email/Phone
2
SVP, Head Business DevelopmentReveal Email/Phone
3
SVP & Head ResearchReveal Email/Phone
4
ControllerReveal Email/Phone
5
VP Human ResourcesReveal Email/Phone
6
SVP Regulatory AffairsReveal Email/Phone
7
SVP and Head CMCReveal Email/Phone
8
VP, Head Investor RelationsReveal Email/Phone
9
SVP, Intellectual Property AffairsReveal Email/Phone
10
SVP, Intellectual Property Affairs (f/k/a Intrexon Corporation)Reveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is Precigen?

DNA Sciences, Inc. is an applied genetics company focused on developing DNA diagnostics for critical medical and therapeutic decisions. The company utilizes DNA based tests in clinical trials to understand differential response to medication and diagnose disease state. It has a combination of research and GLP/CLIA facilities and is involved in a broad range of genetics activities extending from discovery and development to genetic testing services. DNA Sciences is also a leading provider of pharmacogenetic services to the pharmaceutical industry through its wholly-owned subsidiary, DNA Sciences Laboratories (formerly PPGx, Inc.). DNA Sciences is based in Fremont, Calif. and was founded in May 1998. Visit the company's website at www.dna.com.

keywords:N/A

$525.8M

Total Funding

105

Number of Employees

$99M

Revenue (est)

-1%

Employee Growth %

$667.8M

Valuation

N/A

Accelerator

Precigen News

2022-04-20 - Brokerages Anticipate Precigen, Inc. (NYSE:PGEN) Will Post Quarterly Sales of $20.90 Million

According to Zacks, analysts expect that Precigen will report full-year sales of $92.70 million for the current year, with estimates ranging...

2022-04-20 - Precigen, Inc. (NYSE:PGEN) Expected to Post Quarterly Sales ...

Equities research analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to post $20.90 million in sales for the current quarter,...

2022-04-19 - Precigen, Inc. (NYSE:PGEN) Expected to Post Earnings of ...

Brokerages expect Precigen, Inc. (NYSE:PGEN – Get Rating) to announce earnings per share of ($0.14) for the current fiscal quarter,...

2021-08-02 - Precigen : to Announce Second Quarter and First Half 2021 Financial Results on August 9th

GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial r ...

2021-08-02 - Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th

GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34.7M10515%N/A
#2
$23.8M1055%N/A
#3
$23.6M1173%N/A
#4
$29M11812%N/A
#5
$32.7M119-1%N/A